MAPS Technology Platform
Affinivax’s proprietary, next-generation vaccine technology, called MAPS for Multiple Antigen Presenting System, is designed to create novel vaccines that provide the broadest protection against challenging infectious diseases.
Strong Intellectual Property
Affinivax has an exclusive license from Boston Children’s Hospital to intellectual property on the MAPS technology platform, initially developed at Boston Children’s in the laboratories of Richard Malley, M.D., Affinivax’s scientific founder. The licensed intellectual property covers proprietary compositions and methods of use pertaining to the binding proteins, biotin and rhizavidin, as well as several conserved protein antigens. With this strong patent portfolio, Affinivax is advancing plans for a robust program in a number of priority areas for vaccine innovation today.